サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1584128

有毛細胞白血病治療市場：薬剤クラス別、治療タイプ別、投与経路別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、予想、2024年～2032年

Hairy Cell Leukemia Treatment Market, By Drug Class, By Therapy Type, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 269 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
有毛細胞白血病治療市場：薬剤クラス別、治療タイプ別、投与経路別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、予想、2024年～2032年
出版日: 2024年10月26日
発行: AnalystView Market Insights
ページ情報: 英文 269 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

有毛細胞白血病治療の市場規模は2023年に1億290万米ドルとなり、2024年から2032年にかけてCAGR 5.40%で拡大

有毛細胞白血病治療市場-市場力学

認知度の向上と早期診断が有毛細胞白血病治療市場の成長を促進

早期発見によって患者の5年生存率が90%以上になることを示す米国がん協会の報告書が強調しているように、認知度の向上と早期診断が有毛細胞白血病治療市場の成長を大きく後押ししています。白血病リンパ腫協会（Leukemia &Lymphoma Society）などのヘルスケア団体は、有毛細胞白血病の症状や適時診断の重要性についての理解を深めるため、医療従事者と一般市民の双方を対象とした教育キャンペーンを開始しました。このような取り組みにより、スクリーニングの実施や専門医療へのアクセスが改善され、より早期の段階で患者を特定することが容易になりました。さらに、クラドリビンのような標的治療薬を含む新しい治療選択肢が利用可能になったことで、より早期の介入が促されています。米国では年間約3,000人が新たに有毛細胞白血病に罹患していると推定されており、患者の転帰を改善し、この稀ながんの全体的な治療状況を改善するためには、認識と早期診断に焦点を当てることが重要です。

有毛細胞白血病治療市場 - 主要洞察

弊社のリサーチアナリストの分析によると、世界市場は予測期間（2024年～2032年）にCAGR約5.40%で毎年成長すると推定されます。

薬剤クラス別では、プリンアナログが2023年に最大の市場シェアを示すと予測されています。

治療タイプ別では、化学療法が2023年の主要タイプでした。

投与経路別では、静脈内投与が2023年の主要タイプでした。

地域別では、北米が2023年の収益でトップでした。

有毛細胞白血病治療市場 - セグメンテーション分析：

世界の有毛細胞白血病治療市場は、薬剤クラス別、治療タイプ別、投与経路別、エンドユーザー別、地域別に区分されます。

薬剤クラス別では、プリンアナログ、BRAF阻害剤、CD20モノクローナル抗体の3つのカテゴリーに分けられます。プリンアナログは、有毛細胞白血病の治療において確立された有効性、特にクラドリビンにより、最も高い優先順位を占めています。CD20モノクローナル抗体も有効であるが、一般的には併用療法で使用されます。

治療タイプ別では、化学療法、標的療法、免疫療法、併用療法の4つのカテゴリーに分けられます。化学療法は、特にクラドリビンのような薬剤が標準治療となっており、有毛細胞白血病の最優先治療であることに変わりはないです。BRAFのような特定の遺伝子変異に焦点を当てた標的療法がこれに続く。免疫療法が台頭してきているが一般的ではなく、併用療法が耐性症例に使用されるようになってきています。

有毛細胞白血病治療市場 - 地理的洞察

北米は有毛細胞白血病治療市場の主要地域であり、高度なヘルスケアインフラと研究開発への多額の投資が牽引しています。2023年、米国食品医薬品局（FDA）は、有毛細胞白血病に関連する特定の変異を標的とする新しい治療を承認し、患者の治療選択肢を強化しました。また、米国がん協会は、米国における早期診断の取り組みが生存率の改善につながったと報告しており、この地域の市場における優位性に寄与しています。欧州では、ドイツや英国などの国々が、患者の予後改善に有望な標的免疫療法を含む新規療法に焦点を当てた臨床試験で躍進しています。これらの地域では、製薬会社と研究機関との協力体制がイノベーションを促進しています。例えば、バイオテクノロジー企業と主要ながん研究センターとの提携は、有毛細胞白血病の個別化治療計画の開発を促進することを目的としています。世界的に認知度が高まるにつれ、最先端の治療法へのアクセスは改善し続け、この稀ながんに対するより強固な治療状況が形成されつつあります。

有毛細胞白血病治療市場 - 競合情勢：

有毛細胞白血病治療市場の競合情勢は、Novartis社やTeva Pharmaceuticals社などの企業が治療開発で大きく前進している北米が主に牽引しています。2023年、Novartis社は有毛細胞白血病の治療薬として定評のあるクラドリビンの新製剤の発売を発表し、患者のコンプライアンスと治療成績の向上を目指しました。また、Teva社と白血病リンパ腫協会とのパートナーシップは、十分な治療を受けていない人々の認知度を高め、治療へのアクセスを改善することに重点を置いています。一方、欧州では、Roche社が治療効果の向上を目指した新規標的治療薬の臨床試験を実施し、ポートフォリオの拡充を図っています。また、Giliad Sciences社によるKite Pharma社の買収は、有毛細胞白血病に適応可能な細胞療法に焦点を当て、血液悪性腫瘍分野での地位を強化しました。これらの発展は、この稀な白血病患者の治療選択肢を前進させるためには、協力と革新が鍵となるダイナミックで競合的な環境を反映しています。

目次

第1章 有毛細胞白血病治療の市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 有毛細胞白血病治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 有毛細胞白血病治療の産業調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 有毛細胞白血病治療市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 有毛細胞白血病治療の市場情勢

  • 有毛細胞白血病治療市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 有毛細胞白血病治療市場 - 薬剤クラス別

  • 概要
    • 薬剤クラス別のセグメントシェア分析
    • プリン類似体
    • BRAF阻害剤
    • CD20モノクローナル抗体

第8章 有毛細胞白血病治療市場 - 治療タイプ別

  • 概要
    • 治療タイプ別のセグメントシェア分析
    • 化学療法
    • 標的療法
    • 免疫療法
    • 併用療法

第9章 有毛細胞白血病治療市場 - 投与経路別

  • 概要
    • 投与経路別のセグメントシェア分析
    • 経口
    • 静脈内

第10章 有毛細胞白血病治療市場 - エンドユーザー別

  • 概要
    • エンドユーザー別のセグメントシェア分析
    • 病院
    • 腫瘍科クリニック
    • 研究機関

第11章 有毛細胞白血病治療市場 - 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析 - 有毛細胞白血病治療業界

  • 競合ダッシュボード
  • 企業プロファイル
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Johnson &Johnson
    • Merck &Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Others

第13章 アナリストの全方位展望

目次
Product Code: ANV4111

REPORT HIGHLIGHT

Hairy Cell Leukemia Treatment Market size was valued at USD 102.90 Million in 2023, expanding at a CAGR of 5.40% from 2024 to 2032.

The Hairy Cell Leukemia Treatment Market focuses on therapies for hairy cell leukemia (HCL), a rare type of blood cancer characterized by the overproduction of abnormal B lymphocytes. It accounts for approximately 2% of all leukemia cases, making targeted treatment options critical for affected patients. Increased awareness and early diagnosis are contributing to market growth, with organizations like the Leukemia & Lymphoma Society reporting a significant rise in new treatment modalities that improve patient outcomes. However, the market faces challenges, including the limited number of available treatment options and high costs associated with newer therapies, which may restrict access for some patients. Additionally, the rarity of the disease can lead to difficulties in recruitment for clinical trials, impacting research and development. Opportunities exist in the development of novel therapies, such as targeted agents and immunotherapies, which show promise in improving treatment efficacy. Furthermore, ongoing research into the molecular mechanisms of HCL presents avenues for innovative treatment strategies that could enhance patient quality of life and outcomes.

Hairy Cell Leukemia Treatment Market- Market Dynamics

Increased Awareness and Early Diagnosis Fuel Growth in the Hairy Cell Leukemia Treatment Market

Increased awareness and early diagnosis are significantly fueling growth in the Hairy Cell Leukemia Treatment Market, as highlighted by the American Cancer Society's reports indicating that early detection can lead to a more than 90% five-year survival rate for patients. Advocacy groups such as the Leukemia & Lymphoma Society have launched educational campaigns aimed at both healthcare professionals and the public to enhance understanding of hairy cell leukemia symptoms and the importance of timely diagnosis. These initiatives have resulted in improved screening practices and access to specialized care, facilitating the identification of patients at earlier stages of the disease. Additionally, the availability of newer treatment options, including targeted therapies like cladribine, is encouraging earlier intervention. With an estimated incidence rate of about 3,000 new cases of hairy cell leukemia diagnosed annually in the United States, the focus on awareness and early diagnosis is critical in improving patient outcomes and enhancing the overall treatment landscape for this rare cancer.

Hairy Cell Leukemia Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.40% over the forecast period (2024-2032)

Based on Drug Class segmentation, Purine Analogues was predicted to show maximum market share in the year 2023

Based on Therapy Type segmentation, Chemotherapy was the leading type in 2023

Based on Route of Administration segmentation, Intravenous (IV) administration was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Hairy Cell Leukemia Treatment Market- Segmentation Analysis:

The Global Hairy Cell Leukemia Treatment Market is segmented on the basis of Drug Class, Therapy Type, Route of Administration, End-User, and Region.

The market is divided into three categories based on Drug Class: Purine Analogues, BRAF Inhibitors, and CD20 Monoclonal Antibodies. Purine analogs hold the highest priority due to their established efficacy in treating hairy cell leukemia, particularly cladribine. BRAF inhibitors follow, targeting specific mutations in some patients, while CD20 monoclonal antibodies are also effective but are generally used in combination therapies.

The market is divided into four categories based on Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Combination Therapy. Purine Analogues, BRAF Inhibitors, and CD20 Monoclonal Antibodies. Chemotherapy remains the highest priority therapy for hairy cell leukemia, particularly with drugs like cladribine being the standard of care. Targeted therapy follows, focusing on specific genetic mutations such as BRAF. Immunotherapy is emerging but less common, while combination therapy is increasingly used for resistant cases.

Hairy Cell Leukemia Treatment Market- Geographical Insights

North America is the leading region in the Hairy Cell Leukemia Treatment Market, driven by advanced healthcare infrastructure and significant investments in research and development. In 2023, the U.S. Food and Drug Administration (FDA) approved a new therapy, targeting specific mutations associated with hairy cell leukemia, enhancing treatment options for patients. The American Cancer Society has also reported that early diagnosis initiatives in the U.S. have led to improved survival rates, contributing to the region's prominence in the market. In Europe, countries like Germany and the UK are making strides with clinical trials focusing on novel therapies, including targeted immunotherapies, which have shown promise in improving patient outcomes. Collaborative efforts between pharmaceutical companies and research institutions in these regions are fostering innovation; for instance, a partnership between a biotech firm and a major cancer research center aims to expedite the development of personalized treatment plans for hairy cell leukemia. As awareness increases globally, access to cutting-edge therapies continues to improve, shaping a more robust treatment landscape for this rare cancer.

Hairy Cell Leukemia Treatment Market- Competitive Landscape:

The competitive landscape of the Hairy Cell Leukemia Treatment Market is primarily led by North America, where companies like Novartis and Teva Pharmaceuticals are making significant strides in therapy development. In 2023, Novartis announced the launch of a new formulation of cladribine, a well-established treatment for hairy cell leukemia, aimed at enhancing patient compliance and treatment outcomes. In addition, the partnership between Teva and the Leukemia & Lymphoma Society has focused on increasing awareness and improving access to treatment for underserved populations. Meanwhile, in Europe, Roche has been expanding its portfolio with ongoing clinical trials for novel targeted therapies that aim to enhance treatment efficacy. The acquisition of Kite Pharma by Gilead Sciences has also fortified its position in the hematologic malignancies sector, focusing on cell therapies that could be adapted for hairy cell leukemia. These developments reflect a dynamic and competitive environment where collaboration and innovation are key to advancing treatment options for patients with this rare form of leukemia.

Recent Developments:

In August 2022, the U.S. FDA approved AstraZeneca's tablet formulation of Calquence for treating small lymphocytic leukemia (SLL), chronic lymphocytic leukemia (CLL), and relapsed or refractory mantle cell lymphoma (MCL), enhancing the company's product portfolio and market presence.

In September 2018, the FDA approved AstraZeneca's Lumoxiti injection for treating adult patients with relapsed or refractory hairy cell leukemia (HCL) who had undergone at least two prior systemic therapies, enhancing the company's product offerings and increasing revenue potential.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HAIRY CELL LEUKEMIA TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Others

GLOBAL HAIRY CELL LEUKEMIA TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Purine Analogues
  • BRAF Inhibitors
  • CD20 Monoclonal Antibodies

GLOBAL HAIRY CELL LEUKEMIA TREATMENT MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Combination Therapy

GLOBAL HAIRY CELL LEUKEMIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous

GLOBAL HAIRY CELL LEUKEMIA TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Oncology Clinics
  • Research Institutions

GLOBAL HAIRY CELL LEUKEMIA TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Hairy Cell Leukemia Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Hairy Cell Leukemia Treatment Market Snippet by Drug Class
    • 2.1.2. Hairy Cell Leukemia Treatment Market Snippet by Therapy Type
    • 2.1.3. Hairy Cell Leukemia Treatment Market Snippet by Route of Administration
    • 2.1.4. Hairy Cell Leukemia Treatment Market Snippet by End-User
    • 2.1.5. Hairy Cell Leukemia Treatment Market Snippet by Country
    • 2.1.6. Hairy Cell Leukemia Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Hairy Cell Leukemia Treatment Key Market Trends

  • 3.1. Hairy Cell Leukemia Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Hairy Cell Leukemia Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Hairy Cell Leukemia Treatment Market Opportunities
  • 3.4. Hairy Cell Leukemia Treatment Market Future Trends

4. Hairy Cell Leukemia Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Hairy Cell Leukemia Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Hairy Cell Leukemia Treatment Market Landscape

  • 6.1. Hairy Cell Leukemia Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Hairy Cell Leukemia Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Purine Analogues
    • 7.1.3. BRAF Inhibitors
    • 7.1.4. CD20 Monoclonal Antibodies

8. Hairy Cell Leukemia Treatment Market - By Therapy Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
    • 8.1.2. Chemotherapy
    • 8.1.3. Targeted Therapy
    • 8.1.4. Immunotherapy
    • 8.1.5. Combination Therapy

9. Hairy Cell Leukemia Treatment Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Intravenous

10. Hairy Cell Leukemia Treatment Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Oncology Clinics
    • 10.1.4. Research Institutions

11. Hairy Cell Leukemia Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Hairy Cell Leukemia Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Hairy Cell Leukemia Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Hairy Cell Leukemia Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Hairy Cell Leukemia Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Hairy Cell Leukemia Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Hairy Cell Leukemia Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. AbbVie Inc.
    • 12.2.2. Amgen Inc.
    • 12.2.3. AstraZeneca PLC
    • 12.2.4. Bayer AG
    • 12.2.5. Bristol-Myers Squibb Company
    • 12.2.6. Eli Lilly and Company
    • 12.2.7. F. Hoffmann-La Roche AG
    • 12.2.8. Gilead Sciences, Inc.
    • 12.2.9. GlaxoSmithKline plc
    • 12.2.10. Johnson & Johnson
    • 12.2.11. Merck & Co., Inc.
    • 12.2.12. Novartis AG
    • 12.2.13. Pfizer Inc.
    • 12.2.14. Sanofi S.A.
    • 12.2.15. Takeda Pharmaceutical Company Limited
    • 12.2.16. Teva Pharmaceutical Industries Ltd.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us